Publications by authors named "J S Durant"
Objective: Multiple-Locus Variable Number of Tandem Repeats (VNTR) Analysis (MLVA) is widely used to subtype pathogens causing foodborne and waterborne disease outbreaks. The MLVAType shiny application was previously designed to extract MLVA profiles of Vibrio cholerae isolates from whole-genome sequencing (WGS) data, and provide backward compatibility with traditional MLVA typing methods. The previous development and validation work was conducted using short (pair-end 300 and 150 nt long) reads from Illumina MiSeq and Hiseq sequencing.
View Article and Find Full Text PDFArticle Synopsis
- - Varoglutamstat is a new small molecule being tested for early Alzheimer's disease, targeting glutaminyl cyclase to potentially reduce toxic forms of amyloid-β and neuroinflammatory cytokines.
- - The VIVA-MIND trial is structured in two phases, with phase 2A focusing on determining the safe dose and phase 2B evaluating the drug's effectiveness and long-term safety through a 72-week period.
- - The trial's design allows for continuous safety assessments and adaptive decision-making based on cognitive function and electroencephalogram changes, aiming to confirm varoglutamstat's unique ability to tackle several aspects of Alzheimer's pathology.
Population dynamics depend on trophic interactions that are affected by climate change. The rise in sea temperature is associated with the disappearance of sea ice in the Arctic. In the Arctic part of the Barents Sea, Atlantic cod, capelin and polar cod are three fish populations that interact and are confronted with climate-induced sea ice reductions.
View Article and Find Full Text PDFArticle Synopsis
- Conducted whole-genome sequencing on 263 cholera O1 isolates from four provinces in the Democratic Republic of Congo between 2018 and 2024, identifying them as part of the AFR10 lineage.
- The study revealed that while core genomic changes were minimal, significant rearrangements in the CTX prophage were noted in recent isolates from 2022-2024.
- AFR10e showed widespread distribution across provinces, while AFR10d appeared to be extinct after 2020, highlighting important shifts in cholera strain characteristics.
Article Synopsis
- Benfotiamine is being tested as a new oral treatment option for early Alzheimer's disease (AD), potentially enhancing the effects of existing therapies targeting amyloid.
- A 72-week randomized, double-blind, placebo-controlled trial will investigate its safety, tolerability, and efficacy in 406 participants, starting with a phase 2A to find the optimal dose before moving to phase 2B.
- The trial's innovative design allows for a smooth transition between phases, aiming to confirm benefits through specific cognitive and safety assessments.